Builders Firstsource (BLDR) Shareholder Frontfour Capital Group Has Cut Its Position as Valuation Declined; As Bristol Myers Squibb Co (BMY) Stock Value Declined, Cambiar Investors Lowered Holding by $7.84 Million

June 19, 2018 - By Dolores Ford

Builders FirstSource, Inc. (NASDAQ:BLDR) Logo

Frontfour Capital Group Llc decreased its stake in Builders Firstsource Inc (BLDR) by 35.57% based on its latest 2018Q1 regulatory filing with the SEC. Frontfour Capital Group Llc sold 116,834 shares as the company’s stock declined 4.97% with the market. The hedge fund held 211,601 shares of the consumer services company at the end of 2018Q1, valued at $4.20 million, down from 328,435 at the end of the previous reported quarter. Frontfour Capital Group Llc who had been investing in Builders Firstsource Inc for a number of months, seems to be less bullish one the $2.16B market cap company. It closed at $18.88 lastly. It is down 41.13% since June 19, 2017 and is uptrending. It has outperformed by 28.56% the S&P500. Some Historical BLDR News: 16/04/2018 – MUGATU: BLUE LINX? $BXCLE TIGRE?BUILDERS FIRST SOURCE? $BLDR THEY’RE THE SAME LOOK! DOESN’T ANYONE NOTICE THIS?I FEEL… h; 09/05/2018 – BUILDERS FIRSTSOURCE INC – EXPECT TO GENERATE $170-190 MLN IN CASH FROM OPERATIONS AND INVESTING IN 2018; 09/05/2018 – BUILDERS FIRSTSOURCE 1Q ADJ EPS 24C; 09/05/2018 – Builders FirstSource 1Q EPS 20c; 28/05/2018 – Builders FirstSource Access Event Set By Seaport for Jun. 4-5; 16/05/2018 – S&PGR Raises Builders FirstSource Rtgs To ‘BB-‘; Otlk Stable; 21/04/2018 – DJ Builders FirstSource Inc, Inst Holders, 1Q 2018 (BLDR); 09/05/2018 – BUILDERS FIRSTSOURCE 1Q GROSS MARGIN +24.2%; 09/05/2018 – BUILDERS FIRSTSOURCE 1Q GROSS MARGIN +24.2%, EST. +24.2%; 16/05/2018 – S&P REVISES BUILDERS FIRSTSOURCE INC. TO RATING ‘BB-‘ FROM ‘B+’

Cambiar Investors Llc decreased its stake in Bristol Myers Squibb Co (BMY) by 18.19% based on its latest 2018Q1 regulatory filing with the SEC. Cambiar Investors Llc sold 124,498 shares as the company’s stock declined 23.11% with the market. The institutional investor held 559,967 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $35.42M, down from 684,465 at the end of the previous reported quarter. Cambiar Investors Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $87.69 billion market cap company. The stock decreased 2.10% or $1.15 during the last trading session, reaching $53.65. About 8.52 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since June 19, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: 30/04/2018 – Merck Has Submitted Keytruda Combination For FDA Approval — MarketWatch; 06/03/2018 – Bristol-Myers Squibb’s Opdivo(R) (nivolumab) Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing; 02/04/2018 – Bristol-Myers Squibb to Hold Investor Event to Discuss AACR Highlights; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – IN STUDY, TWO-YEAR SURVIVAL RATE FOR OPDIVO WAS 16.9% VERSUS 6.0% FOR STANDARD CHEMOTHERAPY; 11/04/2018 – Rhode Island DoA: Bristol North and East Burial Grounds Commission Wed, 4/11/2018, 7:00 PM; 05/04/2018 – USGS: M 5.2 – 145km NNE of Bristol Island, South Sandwich Islands; 26/04/2018 – Bristol-Myers: Noncurrent Pension Liabilities $434 Million at March 31; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – SAFETY PROFILE FOR OPDIVO AT TWO-YEAR FOLLOW-UP WAS CONSISTENT WITH PREVIOUS ANALYSES FROM STUDY; 23/05/2018 – Merck’s Keytruda succeeds late-stage lung cancer study; 25/03/2018 – ONO: OPDIVO APPROVED FOR WIDER USE IN HODGKIN LYMPHOMA IN KOREA

Investors sentiment decreased to 0.83 in 2018 Q1. Its down 0.11, from 0.94 in 2017Q4. It is negative, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. Tower Bridge Advsrs has 0% invested in Bristol-Myers Squibb Company (NYSE:BMY). Edge Wealth Management reported 275 shares stake. Windsor Management holds 0.46% or 15,517 shares in its portfolio. 55,719 were accumulated by Partner Investment Mgmt L P. The Maine-based Bath Savings has invested 0.26% in Bristol-Myers Squibb Company (NYSE:BMY). Baystate Wealth Mgmt Ltd, a Massachusetts-based fund reported 837 shares. Perkins Coie owns 3,084 shares or 0.1% of their US portfolio. Beaumont Prns has invested 0.09% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Timber Creek Mgmt Limited Co holds 0.06% or 1,625 shares in its portfolio. Willis Investment Counsel reported 0.82% stake. Glacier Peak Capital Limited Liability Company reported 20,000 shares or 0.77% of all its holdings. Capital Rech Invsts invested 0.02% in Bristol-Myers Squibb Company (NYSE:BMY). Smith Salley invested in 0.1% or 8,457 shares. Tdam Usa, Ontario – Canada-based fund reported 98,846 shares. Cornerstone Advsr holds 0.34% in Bristol-Myers Squibb Company (NYSE:BMY) or 7,815 shares.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on July, 26. They expect $0.87 EPS, up 17.57% or $0.13 from last year’s $0.74 per share. BMY’s profit will be $1.42 billion for 15.42 P/E if the $0.87 EPS becomes a reality. After $0.94 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -7.45% negative EPS growth.

Cambiar Investors Llc, which manages about $8.42 billion and $6.30 billion US Long portfolio, upped its stake in Philip Morris Intl Inc (NYSE:PM) by 2.22M shares to 2.53 million shares, valued at $251.79 million in 2018Q1, according to the filing. It also increased its holding in Viasat Inc (NASDAQ:VSAT) by 74,606 shares in the quarter, for a total of 79,154 shares, and has risen its stake in Lloyds Banking Group Plc (NYSE:LYG).

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, September 29 by UBS. The rating was maintained by Credit Suisse with “Hold” on Wednesday, August 16. The firm has “Hold” rating by Jefferies given on Friday, April 13. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Thursday, July 27. Piper Jaffray has “Hold” rating and $6000 target. The firm earned “Market Perform” rating on Friday, April 27 by BMO Capital Markets. As per Friday, April 20, the company rating was maintained by Cowen & Co. Jefferies upgraded the shares of BMY in report on Monday, December 19 to “Buy” rating. The firm earned “Equal-Weight” rating on Friday, September 9 by Barclays Capital. The stock has “Buy” rating by Citigroup on Tuesday, September 20. Berenberg downgraded the stock to “Hold” rating in Thursday, August 11 report.

Since April 30, 2018, it had 1 buying transaction, and 0 selling transactions for $249,948 activity.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Streetinsider.com which released: “Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology …” on June 15, 2018, also Bizjournals.com with their article: “Why Big Pharma is finally discovering the Bay Area” published on May 23, 2018, Seekingalpha.com published: “Bristol-Myers Top NASH Contenders” on June 12, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Merck up 2% premarket on positive Keytruda data; Bristol-Myers down 2%” published on June 04, 2018 as well as Seekingalpha.com‘s news article titled: “Nektar down 24% premarket on Opdivo + NKTR-214 data” with publication date: June 04, 2018.

Frontfour Capital Group Llc, which manages about $447.90 million and $499.52M US Long portfolio, upped its stake in Ishares Tr (Put) (IWM) by 228,500 shares to 424,600 shares, valued at $64.47M in 2018Q1, according to the filing. It also increased its holding in Spdr S&P 500 Etf Tr (Put) (SPY) by 313,300 shares in the quarter, for a total of 607,500 shares, and has risen its stake in Fiat Chrysler Automobiles N.

Among 11 analysts covering Builders Firstsource (NASDAQ:BLDR), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Builders Firstsource had 28 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Sunday, January 21. On Thursday, June 7 the stock rating was maintained by FBR Capital with “Buy”. The stock of Builders FirstSource, Inc. (NASDAQ:BLDR) has “Buy” rating given on Friday, November 10 by FBR Capital. As per Friday, March 2, the company rating was maintained by SunTrust. The firm has “Buy” rating given on Thursday, November 9 by SunTrust. As per Tuesday, June 27, the company rating was maintained by FBR Capital. On Friday, November 10 the stock rating was maintained by Citigroup with “Neutral”. The rating was maintained by FBR Capital on Thursday, March 1 with “Buy”. The rating was downgraded by Zacks on Monday, August 10 to “Buy”. The firm has “Neutral” rating given on Thursday, September 10 by Citigroup.

Since March 1, 2018, it had 0 buys, and 7 selling transactions for $10.48 million activity. $683,580 worth of Builders FirstSource, Inc. (NASDAQ:BLDR) was sold by MILGRIM BRETT N. 11,972 shares valued at $256,680 were sold by Jackson Peter M. on Thursday, March 8. 50,000 shares were sold by Tolly Morris E, worth $1.06 million on Thursday, March 1. CROW M CHAD sold $1.14M worth of stock. 194,043 shares were sold by MCALEENAN DONALD F, worth $4.20 million on Monday, March 12.

Analysts await Builders FirstSource, Inc. (NASDAQ:BLDR) to report earnings on August, 2. They expect $0.56 EPS, up 51.35% or $0.19 from last year’s $0.37 per share. BLDR’s profit will be $64.19 million for 8.43 P/E if the $0.56 EPS becomes a reality. After $0.24 actual EPS reported by Builders FirstSource, Inc. for the previous quarter, Wall Street now forecasts 133.33% EPS growth.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: